Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide vs Flutamide in CRPC
NCT02918968Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enzalutamide in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Time to PSA Progression With 1st Line AAT up to 38 months. Started Nov 2016; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02918968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918968.